Hpv Cervical Cancer Statistics

by Rachel on July 2, 2010

In 2006, 15,000 to 16,000 women likely to die from this silent killer. Statistics ovarian cancer HPV is the fifth most common cause of death among women and is responsible for approximately five percent of cancer deaths. Chances are your doctor may have misdiagnosed. Is often the case. A recent British study found 60 percent of British family doctors had mistaken for his patients.

Three quarters of British doctors, mistakenly, that the symptoms occurred in the late stages of ovarian cancer. Based on this information, it should not be surprising that Great Britain has one of the lowest survival rates for ovarian cancer in the Western world – are diagnosed 6,800 cases a year, killing more than 4,600 .

A similar discovery was purchased by researchers at the University of California, who announced last year, “Four in 10 women with symptoms of ovarian cancer they tell their doctor for at least four months – and also long as a year – before they are diagnosed. After studying nearly 2,000 women with ovarian cancer, researchers have found doctors:

• named First performed abdominal imaging or gastrointestinal procedures instead of the corresponding pool imaging and / or CA-125 (a blood test to detect ovarian cancer who can).

• Only 25 percent of patients with symptoms of ovarian cancer have been reported at least four months before the diagnosis was given pelvic imaging or CA-125 blood tests.

Patients with early symptoms are often diagnosed correctly. Abdominal imaging or diagnostic gastrointestinal studies are less likely to detect cancer of the ovary. According to the American Cancer Society Web site: “The most common symptom is back pain, followed by fatigue, bloating, constipation, abdominal pain and urgency. These symptoms tend to occur very frequently and become more difficult with time. Most women with ovarian cancer have at least two of these symptoms. ”

When a woman is the fourth stage of ovarian cancer, their treatment is often the first line carboplatin, paclitaxel and cisplatin in ovarian cancer chemotherapy as individuals. Initially, the cancer is contained in one or both ovaries. The second phase has cancer of the fallopian tubes or other pelvic tissues, such as the dissemination of the bladder or rectum. If the cancer has spread beyond the pelvis into the abdominal cavity, particularly when tumor growth was more than two inches above the lining of the stomach, then reached for ovarian cancer is the third step. The fourth and final stage of ovarian cancer is reached when the body’s other organs, like liver or lungs distributed.

Lung Cancer Secrets Revealed, click here

If detected early, survival rates can be as high as 90 percent. Detected at an advanced stage the survival rate of 30-40 per cent fall. Several imaging studies such as computed tomography (CT), magnetic resonance imaging (MRI) and ultrasound can confirm whether a mass pool is available. A laparoscopy may help a doctor to examine the ovaries and other tissues of the pelvis, to plan surgery, or to determine the stage of ovarian cancer. Confirmation of a biopsy or tissue samples, it would if the cancer in the pelvic area, and help to identify, as is well advanced. A blood test elevated CA-125 usually provides an advanced cancer has progressed.

About 50 percent of patients with ovarian cancer are deposited at an advanced stage when the correct diagnosis. Only 10-14 percent of women with advanced cancer may survive more than five years.

Therapy Evaluation

Although research shows drinking black (or green) tea or ginkgo biloba below the herbal supplement may be useful as a preventive measure to reduce or risk of a woman only a few options if their cancer has increased at an advanced stage. Initially, the face of a woman to remove the tumor and possibly one or two ovaries, in order to increase their chances of survival. In addition, chemotherapy is their choice.

A major problem with the side effects of chemotherapy. Perhaps more advanced cancer, the lower, thus reducing the potential for survival. Survival rates have not changed much over the last fifteen years. Chemotherapy can increase survival by up to 50 percent. But the quality of life suffers. Side effects and increased toxicity, reduce concomitant chemotherapy, how to spend the survival time prolonged.

Some of the smaller side effects of paclitaxel, such as Medline Plus reports can be diluted nausea, vomiting, loss of appetite, taste changes, or brittle hair, pain in the joints of arms or legs, changes in nail color and / or tingling in hands and toes. More serious side effects include mouth blisters or fatigue. Some side effects may concern unusual bleeding or bruising, dizziness, shortness of breath, fatigue, chest pain, or swallowing. The most common side effect of paclitaxel, a reduction in the number of cells.

Carboplatin has its own list of side effects. It can reduce the production of platelets, which may influence the ability of blood to clot. You can become sluggish, tired or breathless. Nausea, vomiting, anorexia and a general feeling of weakness are common with this chemotherapeutic agent.

The latest generation of drugs such as Eli Lilly’s Gemzar, are hardly commendable. On March 10 said the U.S. Food and Drug Administration (FDA) was skeptical about the benefits of Gemzar Eli Lilly, which is currently used with carboplatin to treat patients with ovarian cancer. The FDA was the second eight months increased survival time, if missed by the association Gemzar carboplatin / the treatment of increased toxicity compared.

In January, reported the New England Journal of Medicine about a remarkable new delivery system of chemotherapy, the so-called “intra-abdominal or intraperitoneal, chemotherapy. Those who received the bath” belly ” as it may now be called by the media survived 16 months longer than those receiving intravenous chemotherapy. The biggest drawback is that 60 percent of women in the study, all six cycles of chemotherapy were completed. Anyone who has survived longer, but only two in five women have been able to advance the final phase of therapy.

A new approach, currently in phase III trials in research centers of more than 60 in United States OvaRex ® MAB, monoclonal antibody, a type of biotech drug from mouse cells. It is tested by a highly respected United Therapeutics, Silver Springs, Maryland base. Its lead product Remodulin, an injection, the treatment of pulmonary arterial hypertension, is currently marketed within and outside the United States. More than 32 million dollars have been spent reviewed, and in the development, OvaRex and can they be available until the 2008th on the market

OvaRex was developed in Canada by a company called ViRexx Medical Corp. and tested for the first time in this country. According to Dr. Lorne Tyrrell, Chief Executive Officer of ViRexx “The complete study has been terminated by the FDA. This is a study in which the drug was granted accelerated approval and orphan drug status.” Dr. Tyrrell is on leave (up OvaRex commercially available) are as professor of medical microbiology and immunology at the University of Alberta, and director of the National Centre of Excellence for Viral Hepatitis research.

OvaRex tested in Canada, was before the Phase III study in the U.S. “There were a number of patients receiving OvaRex,” said Dr. Tyrrell, “We have not really had any negative impact these patients. ” Dr Tyrrell of the proceedings, said: “Once injected intravenously with antigen in the blood binds OvaRex.” An antibody, which is for general purposes to neutralize an antigen. OvaRex After injection, monoclonal antibody binds to the antigen CA-125.

Somehow the body is pushed. But the body is pushed to help “save” themselves from the harmful antigen. If antibodies to the antigen CA-125 OvaRex is linked, the new combined entity identified as harmful. Before that, the antigen migrates through the body, without attracting the attention of defense systems of the body, the dendritic cells to attack and destroy the harmful antigen. Since the body is trained to identify and to zero in a foreign protein, in this case, a mouse protein, it alerts the dendritic cells. Until then tolerate the dendritic cells are “cancer cells. Tolerance is what allows the spread of cancer in the body. OvaRex is that breaking tolerance. The monoclonal antibody is to target and bind only to the floating antigen CA-125.

Dendritic cells do not tolerate the foreign protein. If the antibody binds to antigen floating dendritic cells recognize complexes (antibody-antigen plus) as foreign and devour the new unit. Dendritic cells break the key proteins of this unit, all parties present at the cell surface. At that time, the body’s killer T-Cells has alerted the internal threat to the organization fighting for. Once activated, T cells reproduce and create more killer T cells. Each tumor cells expressing the antigen CA-125 is scheduled for destruction. to move the army of T-cells to attack the tumor of the ovary.

The principle behind OvaRex is reprogrammed to make the immune system of the body’s immune system to prevent the growth and spread of ovarian cancer available. T-it cure ovarian cancer? “In most cases, there is a delay,” said Dr. Tyrrell. “But I think everyone and hopes that, often, in some of these tumors, so that you are using incremental progress careful clinical trials and new therapies. Everything we do to improve the result when you click on long-term benefits of this Search Start, we hope that we will one day be able to cure this disease. We think it’s a step. This has the potential to stimulate an important step in helping to answer Immune to get a better result. I hope one day we could do better if there is a cure. ”

Advanced treatment of lung cancer, click here

Best treatment for lung cancer Click here

Leave a Comment

Previous post:

Next post: